Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Aerobic Capacity, High Intensity Interval Training
Interventions: HIIT, MICT; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: South Burlington, Vermont

Conditions: Tobacco Use Cessation, Tobacco Prevention
Interventions: Surveys, ASPIRE Website, ASPIRE Text-Based Website, Follow Up Survey; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 11 Years to 18 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Acute Kidney Injury
Interventions: Saline, Sodium Nitrite; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide; Radiation · Drug · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Congestive Heart Failure, Renal Insufficiency
Interventions: furosemide and hypertonic saline solution, furosemide; Drug
Lead sponsor: Aspirus Heart and Vascular Institute-Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Wausau, Wisconsin

Conditions: Ovarian Cancer
Interventions: Early detection; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years and older · Female only
Enrollment: 2,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autism Spectrum Disorder, Autism
Interventions: Early Diagnostic Response Model Expanded; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 16 Months to 36 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Non-Hodgkin Lymphoma
Interventions: Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan, Biopsy, Pheresis, Bone Marrow Aspiration and Biopsy, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: Sumithira Vasu; Other
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: High Risk Prostate Cancer
Interventions: BKM120; Drug
Lead sponsor: Won Kim; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Patients Undergoing High Risk PCI.
Interventions: High Risk PCI; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: La Jolla, California • Los Angeles, California • Boston, Massachusetts + 4 more

Conditions: Posterior Cortical Atrophy
Interventions: HD-tDCS sessions, Sham HD-tDCS sessions, HD-tDCS sessions - Open-label (after randomized treatment); Device
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Hot Flashes, Sleep Disorders
Interventions: venlafaxine, zolpidem tartrate, management of therapy complications; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Solid Tumor
Interventions: High-Dose Conformal Radiation Therapy, Pembrolizumab; Radiation · Drug
Lead sponsor: James Larner, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colorectal Cancer
Interventions: CRC screening reminder, CRC Reminder & Short message, CRC Reminder and Navigation Program, CRC Reminder & CRC education; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 74 Years
Enrollment: 3,127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anthocyanins
Interventions: ACRB, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Microsatellite Instability High, Mismatch Repair Deficiency, Colorectal Cancer
Interventions: RT and Anti-PD-1, Anti-PD-1; Combination Product · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Morbid Obesity, High BMI
Interventions: Bupivacaine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions: Bone marrow transplantation, Mesenchymal Stromal Cells; Procedure · Biological
Lead sponsor: Stanford University; Other
Eligibility: 1 Year to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Birmingham, Alabama • Minneapolis, Minnesota

Conditions: HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: 18F-FHBG, Aldesleukin, Cellular Therapy, Computed Tomography, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, Leukapheresis, Melphalan, Plerixafor, Positron Emission Tomography; Radiation · Biological · Procedure + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Frailty
Interventions: Metformin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 90 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions: Enhance health lifestyle changes and medication compliance; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Stanford, California

Conditions: Suicidal Ideation, Suicide Attempt, Anxiety, Depression Disorders
Interventions: Peer Support Services Recovery; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 15 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
Interventions: Vancomycin, Ceftaroline, Daptomycin, Linezolid; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Lung Cancer
Interventions: Cisplatin, Etoposide, Radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 104
States / cities: Birmingham, Alabama • Castro Valley, California • Hayward, California + 74 more

Search by objective public record fields.

Optimizing Aerobic Fitness in Older Adults

Middle and High School Students' Reactions to a Health Interactive Website: ASPIRE Reactions

Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Neoadjuvant BKM120 in High-risk Prostate Cancer

PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI

Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

HDCRT Plus Pembrolizumab in Advanced Malignancies

Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Efficacy Of Quadratus Lumborum II Block For Laparoscopic Sleeve Gastrectomy

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Metformin for Preventing Frailty in High-risk Older Adults

Heart Disease on the Mend

Teen Recovery Through Inspiration, Support, and Empowerment

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer